Insilico Medicine's AI-developed drug rentosertib shows anti-aging effects in Phase III clinical trials
According to GeekPark, 42 participants with an average age of 67 showed “younger” blood markers after four weeks of rentosertib, an AI-designed drug from Insilico Medicine, now in Phase III. The study detected nearly 3,000 proteins with 326 changing significantly, and six independent models concluded their bodies were moving toward a younger state, with clocks regressing by about 3–4 years, and one by nearly 6 years.
Key facts
- 0142 participants with an average age of 67 were studied.
- 02After four weeks on rentosertib, about 3,000 proteins were detected, with 326 showing significant changes.
- 03Six models concluded the participants’ bodies appeared to be moving toward younger ages.
- 04Clocks regressed by about 3–4 years on average, with one clock regressing by nearly 6 years.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.
- 不可逆的人类衰老，快被 AI 破解了 · 极客公园